<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.108248</article-id><article-id pub-id-type="publisher-id">ACM-37072</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200800000_62894227.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  血清CA724、CEA、CA242、CA199联合检验对胃癌的诊断价值分析
  Analysis of the Diagnostic Value of Serum CA724, CEA, CA242, CA199 for Gastric Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>诗</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>丽丽</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>潘</surname><given-names>妮</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>齐</surname><given-names>卫卫</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邱</surname><given-names>文生</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>日照市中心医院，山东 日照</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属医院肿瘤科，山东 青岛；日照市中心医院，山东 日照</addr-line></aff><aff id="aff4"><addr-line>青岛大学附属医院肿瘤科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>08</month><year>2020</year></pub-date><volume>10</volume><issue>08</issue><fpage>1655</fpage><lpage>1662</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨血清CA724、CEA、CA242、CA199联合检验对胃癌的诊断价值。方法：选取2014年2月至2018年1月医院收治的158例胃癌患者作为研究组，依据TNM分期标准分为I~II期组84例和III~IV期组74例；因胃部或上消化道系统症状行胃镜检查90例患者作为对照组，其中胃上皮瘤变48例，慢性萎缩性胃炎42例。抽取2组受试对象肘静脉血5 mL，采用化学发光免疫分析检测血清糖类抗原724 (Carbohydrate antigen724, CA724)、糖类抗原199 (Carbohydrate antigen199, CA199)表达水平，放射免疫法检测糖类抗原242 (Carbohydrate antigen242, CA242)水平，酶联免疫吸附试验法检测癌胚抗原(Carcinoembryonic antigen, CEA)水平，根据血清CA724、CEA、CA242、CA199表达水平绘制ROC曲线，对各指标ROC曲线进行分析。结果：研究组CA724、CEA、CA242、CA199表达水平明显高于对照组[(12.77 &#177; 2.61), (28.36 &#177; 7.30), (33.36 &#177; 9.31), (47.31 &#177; 11.61) vs (8.58 &#177; 2.87), (20.64 &#177; 6.99), (24.87 &#177; 8.90), (40.51 &#177; 9.20)] (U/mL)，差异具有统计学意义(t = 11.697, 8.133, 7.018, 4.763, P &lt; 0.05)；III~IV期胃癌患者血清CA724、CEA、CA242、CA199水平明显高于I~II期[(14.77 &#177; 1.57), (33.77 &#177; 4.55), (41.27 &#177; 5.96), (53.97 &#177; 7.04) vs (10.95 &#177; 1.95), (23.47 &#177; 5.68), (26.23 &#177; 5.03), (42.49 &#177; 9.11)] (U/mL)，差异具有统计学意义(t = 13.426, 12.483, 17.185, 12.617, P &lt; 0.05)。Logistic回归分析显示，CA724、CEA、CA242、CA199是胃癌的独立危险因素，差异具有统计学意义(P &lt; 0.05)；ROC曲线分析显示，血清CA724鉴别胃癌和对照组的AUC为0.864、CEA为0.784、CA242为0.743、CA199为0.692，联合检验为0.940；其中联合检验明显高于CA724、CEA、CA242、CA199单独检测(Z = 4.012, 5.648, 6.680, 7.193, P &lt; 0.05)。结论：胃癌患者血清CA724、CEA、CA242、CA199显著升高，联合检验可提高胃癌的诊断价值，能够为胃癌治疗方案提供可靠依据。
    Objective: To investigate the diagnostic value of serum CA724, CEA, CA242, CA199 for gastric cancer. Method: A total of 158 patients with gastric cancer who were treated in the hospital from February 2014 to January 2018 were selected as the study group. According to the TNM staging criteria, they were divided into the stage I~II group (84 cases) and the stage III~IV group (74 cases). 90 patients with systemic symptoms underwent gastroscopy were selected as the control group, which included 48 cases of gastric epithelioma and 42 cases of chronic atrophic gastritis. The expression levels of carbohydrate antigen 724 (CA724) and carbohydrate antigen 199 (CA199) in two groups were detected by chemiluminescence immunoassay, the carbohydrate antigen 242 (CA242) levels were detected by using radioimmunoassay, and the carcinoembryonic antigen (CEA) levels were detected by using enzyme-linked immunosorbent assay. The ROC curves were drawn according to the serum CA724, CEA, CA242, CA199 expression levels, and the ROC curves of each index were analyzed. Results: The expression levels of CA724, CEA, CA242, CA199 in the study group were significantly higher than those in the control group [(12.77 &#177; 2.61), (28.36 &#177; 7.30), (33.36 &#177; 9.31), (47.31 &#177; 11.61) vs (8.58 &#177; 2.87), (20.64 &#177; 6.99), (24.87 &#177; 8.90), (40.51 &#177; 9.20)] (U/mL), and the differences were statistically significant (t = 11.697, 8.133, 7.018, 4.763, P &lt; 0.05). Serum CA724, CEA, CA242, CA199 levels in patients with stage III~IV gastric cancer are significantly higher than those in stage I~II [(14.77 &#177; 1.57), (33.77 &#177; 4.55), (41.27 &#177; 5.96), (53.97 &#177; 7.04) vs (10.95 &#177; 1.95), (23.47 &#177; 5.68), (26.23 &#177; 5.03), (42.49 &#177; 9.11)] (U/mL), and the differences were statistically significant (t = 13.426, 12.483, 17.185, 12.617, P &lt; 0.05). Logistic regression analysis showed that CA724, CEA, CA242, and CA199 are independent risk factors for gastric cancer, and the differences were statistically significant (P &lt; 0.05). ROC curve analysis showed that serum CA724 identified gastric cancer and the control group with an AUC of 0.864, CEA of 0.784, CA242 of 0.743, CA199 of 0.692, and combined test of 0.940. The AUC of the combined test was significantly higher than the individual tests of CA724, CEA, CA242, and CA199 alone (Z = 4.012, 5.648, 6.680, 7.193, P &lt; 0.05). Conclusion: The serum levels of CA724, CEA, CA242, and CA199 in gastric cancer patients are significantly increased, the combined test of which can improve the diagnostic value of gastric cancer, which can provide a reliable basis for gastric cancer treatment options. 
  
 
</p></abstract><kwd-group><kwd>胃癌，糖类抗原724，癌胚抗原，糖类抗原242，糖类抗原199, Gastric Cancer</kwd><kwd> Carbohydrate Antigen 724</kwd><kwd> Carcinoembryonic Antigen</kwd><kwd> Carbohydrate Antigen 242</kwd><kwd> Carbohydrate Antigen 199</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>血清CA724、CEA、CA242、CA199联合检验对胃癌的诊断价值分析</title><p>宋诗<sup>1,2</sup>，王丽丽<sup>2</sup>，潘妮<sup>2</sup>，齐卫卫<sup>1</sup>，邱文生<sup>1*</sup></p><p><sup>1</sup>青岛大学附属医院肿瘤科，山东 青岛</p><p><sup>2</sup>日照市中心医院，山东 日照</p><disp-formula id="hanspub.37072-formula9"><graphic xlink:href="//html.hanspub.org/file/19-1571482x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年7月26日；录用日期：2020年8月11日；发布日期：2020年8月18日</p><disp-formula id="hanspub.37072-formula10"><graphic xlink:href="//html.hanspub.org/file/19-1571482x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨血清CA724、CEA、CA242、CA199联合检验对胃癌的诊断价值。方法：选取2014年2月至2018年1月医院收治的158例胃癌患者作为研究组，依据TNM分期标准分为I~II期组84例和III~IV期组74例；因胃部或上消化道系统症状行胃镜检查90例患者作为对照组，其中胃上皮瘤变48例，慢性萎缩性胃炎42例。抽取2组受试对象肘静脉血5 mL，采用化学发光免疫分析检测血清糖类抗原724 (Carbohydrate antigen724, CA724)、糖类抗原199 (Carbohydrate antigen199, CA199)表达水平，放射免疫法检测糖类抗原242 (Carbohydrate antigen242, CA242)水平，酶联免疫吸附试验法检测癌胚抗原(Carcinoembryonic antigen, CEA)水平，根据血清CA724、CEA、CA242、CA199表达水平绘制ROC曲线，对各指标ROC曲线进行分析。结果：研究组CA724、CEA、CA242、CA199表达水平明显高于对照组[(12.77 &#177; 2.61), (28.36 &#177; 7.30), (33.36 &#177; 9.31), (47.31 &#177; 11.61) vs (8.58 &#177; 2.87), (20.64 &#177; 6.99), (24.87 &#177; 8.90), (40.51 &#177; 9.20)] (U/mL)，差异具有统计学意义(t = 11.697, 8.133, 7.018, 4.763, P &lt; 0.05)；III~IV期胃癌患者血清CA724、CEA、CA242、CA199水平明显高于I~II期[(14.77 &#177; 1.57), (33.77 &#177; 4.55), (41.27 &#177; 5.96), (53.97 &#177; 7.04) vs (10.95 &#177; 1.95), (23.47 &#177; 5.68), (26.23 &#177; 5.03), (42.49 &#177; 9.11)] (U/mL)，差异具有统计学意义(t = 13.426, 12.483, 17.185, 12.617, P &lt; 0.05)。Logistic回归分析显示，CA724、CEA、CA242、CA199是胃癌的独立危险因素，差异具有统计学意义(P &lt; 0.05)；ROC曲线分析显示，血清CA724鉴别胃癌和对照组的AUC为0.864、CEA为0.784、CA242为0.743、CA199为0.692，联合检验为0.940；其中联合检验明显高于CA724、CEA、CA242、CA199单独检测(Z = 4.012, 5.648, 6.680, 7.193, P &lt; 0.05)。结论：胃癌患者血清CA724、CEA、CA242、CA199显著升高，联合检验可提高胃癌的诊断价值，能够为胃癌治疗方案提供可靠依据。</p><p>关键词 :胃癌，糖类抗原724，癌胚抗原，糖类抗原242，糖类抗原199</p><disp-formula id="hanspub.37072-formula11"><graphic xlink:href="//html.hanspub.org/file/19-1571482x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/19-1571482x8_hanspub.png" /> <img src="//html.hanspub.org/file/19-1571482x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>胃癌(Gastric Cancer, GC)是消化系统常见的恶性肿瘤，其发病率是各类恶性肿瘤的第4位，死亡率居于第2位，严重威胁人们的生命健康 [<xref ref-type="bibr" rid="hanspub.37072-ref1">1</xref>]。调查显示 [<xref ref-type="bibr" rid="hanspub.37072-ref2">2</xref>] 进展期胃癌的5年生存率仅为20%左右。由于胃癌的早期症状不典型，大多数患者发现时已进入中晚期，错过了最佳时机，造成患者预后较差。因此胃癌早期诊断、鉴别对于采取合适的治疗方案具有重要意义。病理组织活检是胃癌的诊断的金标准，然而病理学检测属于创伤性操作，部分患者受年龄及身体状况的影响，配合度往往不高。随着现代医学的不断进步，生化指标在胃癌筛查中发挥出巨大潜力。在胃癌的临床诊断中，采用肿瘤标志物如非特异性抗原进行单独检测，但检测的特异性、敏感性不高，限制了检测指标的临床应用。为此临床上采取多种肿瘤标志物联合检测的方法，以提高特异性和敏感性，对于胃癌的早期诊断具有重要意义。研究证实 [<xref ref-type="bibr" rid="hanspub.37072-ref3">3</xref>] 癌胚抗原、糖蛋白抗原的表达与胃癌的生长、分期、分化、浸润及淋巴结转移密切相关，在胃癌病情进展中起到重要作用。本研究通过联合检测CA724、CEA、CA242、CA199表达水平，探讨对胃癌的诊断鉴别价值，现报道如下。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>本研究经医院伦理委员会审核并批准。选取2014年2月至2018年1月医院收治的158例胃癌患者作为研究组，男94例，女64例，年龄45~76岁，平均(58.94 &#177; 5.03)岁。依据美国癌症联合委员会(American Joint Committee on Cancer, AJCC) [<xref ref-type="bibr" rid="hanspub.37072-ref4">4</xref>] TNM分期标准分为I~Ⅱ期84例和Ⅲ~Ⅳ期74例。纳入标准：1) 入选患者经病理组织学研究证实为原发性胃癌；2) 入组前未发生远方转移；3) 初次患者，术前均为接受放化疗或非甾体药物治疗；4) 术前卡式评分 ≥ 60分，预计生存期3个月以上；5) 告知患者及家属本研究过程，并签署知情同意书。排除标准：1) 入组前近3个月内应用免疫抑制剂者；2) 肝肾功能异常或其他重要器质性病变者；3) 合并代谢性或自身免疫性疾病者；4) 合并其他恶性肿瘤患者；5) 临床资料缺失或中途退出者。同期选取因胃部或上消化道系统症状行胃镜检查90例患者作为对照组，均排除肝肾功能障碍或其他脏器疾病；其中胃上皮瘤变48例，慢性萎缩性胃炎42例。研究组与对照组在性别、年龄等基线资料比较，差异无统计学意义(P &lt; 0.05)，具有可比性。</p></sec><sec id="s4_2"><title>2.2. 方法</title><p>所有研究对象均于清晨空腹采集外周静脉血5 mL，采用TDZ5-BP医用离心机(长沙湘锐离心机有限公司)在室温下以3000 r/min离心10 min (离心半径800&#215;g)，取上层血清，置于−20℃冰箱内保存待测。采用化学发光免疫分析(chemiluminescence immunoassay, CLIA)检测血清CA724、CA199表达水平，仪器为罗氏cobas e 411全自动化学发光免疫分析仪，试剂盒购自瑞士罗氏公司；放射免疫法检测CA242水平，试剂盒购自上海基免实业有限公司；酶联免疫吸附试验法检测CEA水平，试剂盒购自上海润裕生物科技有限公司，所有检测均严格按照试剂盒说明书在实验室内完成。</p></sec><sec id="s4_3"><title>2.3. 统计学方法</title><p>采用SPSS22.0统计学软件对数据进行处理，计量资料采用 x &#175; &#177; s表示，两组间比较采用t检验。计数资料采用百分比表示，差异用卡方或Fishers精确概率法。Logistic回归分析影响胃癌的独立危险因素；根据CA724、CEA、CA242、CA199表达水平绘制工作特征曲线(receiver operator characteristic curve, ROC)，确定最佳临界值，参考ROC曲线下面积(Area Under Curve, AUC)评价各检测指标的诊断效能，以P &lt; 0.05表示差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 2组研究对象CA724、CEA、CA242、CA199表达水平</title><p>研究组CA724、CEA、CA242、CA199表达水平明显高于对照组，差异具有统计学意义(P &lt; 0.05)，见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The expression levels of CA724, CEA, CA242, CA199 for 2 groups of subjects ( x &#175; &#177; s, U/mL</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >CA724</th><th align="center" valign="middle" >CEA</th><th align="center" valign="middle" >CA242</th><th align="center" valign="middle" >CA199</th></tr></thead><tr><td align="center" valign="middle" >研究组</td><td align="center" valign="middle" >158</td><td align="center" valign="middle" >12.77 &#177; 2.61</td><td align="center" valign="middle" >28.36 &#177; 7.30</td><td align="center" valign="middle" >33.36 &#177; 9.31</td><td align="center" valign="middle" >47.31 &#177; 11.61</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >90</td><td align="center" valign="middle" >8.58 &#177; 2.87</td><td align="center" valign="middle" >20.64 &#177; 6.99</td><td align="center" valign="middle" >24.87 &#177; 8.90</td><td align="center" valign="middle" >40.51 &#177; 9.20</td></tr><tr><td align="center" valign="middle" >t值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >11.697</td><td align="center" valign="middle" >8.133</td><td align="center" valign="middle" >7.018</td><td align="center" valign="middle" >4.763</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><p>表1. 2组研究对象CA724、CEA、CA242、CA199表达水平( x &#175; &#177; s, U/mL)</p></sec><sec id="s5_2"><title>3.2. 不同分期胃癌患者血清CA724、CEA、CA242、CA199表达水平</title><p>III~IV期胃癌患者血清CA724、CEA、CA242、CA199水平明显高于I~II期，差异具有统计学意义(P &lt; 0.05)，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The expression levels of serum CA724, CEA, CA242, CA199 for gastric cancer in different stages ( x &#175; &#177; s, U/mL</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >CA724</th><th align="center" valign="middle" >CEA</th><th align="center" valign="middle" >CA242</th><th align="center" valign="middle" >CA199</th></tr></thead><tr><td align="center" valign="middle" >I~Ⅱ期</td><td align="center" valign="middle" >84</td><td align="center" valign="middle" >10.95 &#177; 1.95</td><td align="center" valign="middle" >23.47 &#177; 5.68</td><td align="center" valign="middle" >26.23 &#177; 5.03</td><td align="center" valign="middle" >42.49 &#177; 9.11</td></tr><tr><td align="center" valign="middle" >Ⅲ~Ⅳ期</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >14.77 &#177; 1.57</td><td align="center" valign="middle" >33.77 &#177; 4.55</td><td align="center" valign="middle" >41.27 &#177; 5.96</td><td align="center" valign="middle" >53.97 &#177; 7.04</td></tr><tr><td align="center" valign="middle" >t值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >13.426</td><td align="center" valign="middle" >12.483</td><td align="center" valign="middle" >17.185</td><td align="center" valign="middle" >12.617</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><p>表2. 不同分期胃癌患者血清CA724、CEA、CA242、CA199表达水平( x &#175; &#177; s, U/mL)</p></sec><sec id="s5_3"><title>3.3. 胃癌多因素Logistic回归分析</title><p>Logistic回归分析显示，CA724、CEA、CA242、CA199是胃癌的独立危险因素，差异具有统计学意义(P &lt; 0.05)，见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The multivariate logistic regression analysis of gastric cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >自变量</th><th align="center" valign="middle" >β</th><th align="center" valign="middle" >SE</th><th align="center" valign="middle" >Wald</th><th align="center" valign="middle" >P</th><th align="center" valign="middle" >OR</th><th align="center" valign="middle" >95% CI</th></tr></thead><tr><td align="center" valign="middle" >CA724</td><td align="center" valign="middle" >0.562</td><td align="center" valign="middle" >0.093</td><td align="center" valign="middle" >36.422</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.570</td><td align="center" valign="middle" >0.475~0.684</td></tr><tr><td align="center" valign="middle" >CEA</td><td align="center" valign="middle" >0.148</td><td align="center" valign="middle" >0.032</td><td align="center" valign="middle" >21.401</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.862</td><td align="center" valign="middle" >0.810~0.918</td></tr><tr><td align="center" valign="middle" >CA242</td><td align="center" valign="middle" >0.097</td><td align="center" valign="middle" >0.025</td><td align="center" valign="middle" >14.568</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.908</td><td align="center" valign="middle" >0.864~0.954</td></tr><tr><td align="center" valign="middle" >CA199</td><td align="center" valign="middle" >0.081</td><td align="center" valign="middle" >0.021</td><td align="center" valign="middle" >15.205</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.922</td><td align="center" valign="middle" >0.885~0.960</td></tr></tbody></table></table-wrap><p>表3. 胃癌多因素Logistic回归分析</p></sec><sec id="s5_4"><title>3.4. 血清CA724、CEA、CA242、CA199联合检测对胃癌的诊断效能</title><p>ROC曲线分析显示，血清CA724鉴别胃癌和对照组的AUC 为0.864、CEA为0.784、CA242为0.743、CA199为0.692，联合检验为0.940；其中联合检验明显高于CA724、CEA、CA242、CA199单独检测(Z = 4.012, 5.648, 6.680, 7.193, P &lt; 0.05)，见表4，图1、图2。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> The diagnostic efficacy of serum CA724, CEA, CA242, CA199 for gastric cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >特异性</th><th align="center" valign="middle" >敏感性</th><th align="center" valign="middle" >Youden指数J</th><th align="center" valign="middle" >截断值</th><th align="center" valign="middle" >AUC (95%CI)</th></tr></thead><tr><td align="center" valign="middle" >CA724</td><td align="center" valign="middle" >81.11%</td><td align="center" valign="middle" >75.95%</td><td align="center" valign="middle" >0.571</td><td align="center" valign="middle" >10.94 (U/mL)</td><td align="center" valign="middle" >0.864 (0.817~0.910)</td></tr><tr><td align="center" valign="middle" >CEA</td><td align="center" valign="middle" >62.33%</td><td align="center" valign="middle" >82.91%</td><td align="center" valign="middle" >0.462</td><td align="center" valign="middle" >21.57 (U/mL)</td><td align="center" valign="middle" >0.784 (0.725~0.844)</td></tr><tr><td align="center" valign="middle" >CA242</td><td align="center" valign="middle" >65.56%</td><td align="center" valign="middle" >72.15%</td><td align="center" valign="middle" >0.377</td><td align="center" valign="middle" >27.94 (U/mL)</td><td align="center" valign="middle" >0.743 (0.680~0.805)</td></tr><tr><td align="center" valign="middle" >CA199</td><td align="center" valign="middle" >73.33%</td><td align="center" valign="middle" >61.39%</td><td align="center" valign="middle" >0.347</td><td align="center" valign="middle" >44.92 (U/mL)</td><td align="center" valign="middle" >0.692 (0.625~0.758)</td></tr><tr><td align="center" valign="middle" >联合检验</td><td align="center" valign="middle" >92.22%</td><td align="center" valign="middle" >82.28%</td><td align="center" valign="middle" >0.745</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >0.940 (0.912~0.967)</td></tr></tbody></table></table-wrap><p>表4. 血清CA724、CEA、CA242、CA199联合检测对胃癌的诊断效能</p><p>图1. 血清CA724、CEA、CA242、CA199单独检测的AUC</p><p>图2. 血清CA724、CEA、CA242、CA199联合检测的AUC</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>诊断不及时与复发转移是导致胃癌患者不良预后的重要原因，因此对胃癌患者的早期诊断、鉴别，及时治疗是提高患者生存预后的重要手段。然而胃癌患者早期阶段临床及亚临床症状不典型，易于忽视而造成漏诊，大多数患者确诊时已进入中晚期。病理组织活检是胃癌筛查的重要方式，然而患者进行活检检测属于侵入性操作，增大了患者的痛苦，依从性较差，且费用昂贵，影响了临床应用。肿瘤标志物是在肿瘤病情进展中，肿瘤细胞发生恶性增殖，刺激释放一类生物活性物质。调查显示 [<xref ref-type="bibr" rid="hanspub.37072-ref5">5</xref>] 临床上肿瘤标志物已达100种以上，可分为肿瘤抗原、蛋白质、同工酶等。虽然肿瘤标志物具有无创性的优点，然而大多数肿瘤标志物存在特异性不高，或敏感性较低，这亦是制约肿瘤标志物广泛推广的主要原因。</p><p>CA724在多种恶性肿瘤中均有不同程度表达，朱攀研究显示 [<xref ref-type="bibr" rid="hanspub.37072-ref6">6</xref>] CA724在不同恶性肿瘤患者血清中表达的阳性率为37.95%，而健康对照组血清CA724均在3.8 IU/mL，表明CA724在恶性肿瘤中的特异性较高。谢海涛研究发现 [<xref ref-type="bibr" rid="hanspub.37072-ref7">7</xref>] CA724能够将I~II期胃癌患者和健康对照组、淋巴结转移及浆膜层浸润加以鉴别，提示CA724可作为胃癌肿瘤分期及病情进展状况的肿瘤标志物。进一步研究证实 [<xref ref-type="bibr" rid="hanspub.37072-ref8">8</xref>] CA724在术后肿瘤复发的病情监测方面发挥重要价值，其表达水平的升高是肿瘤复发的独立预后因素。CEA属细胞粘附因子，能够增强肿瘤细胞间粘附反应，影响肿瘤细胞浸润、淋巴结转移及生长方面起到重要作用。研究证实 [<xref ref-type="bibr" rid="hanspub.37072-ref9">9</xref>] 结肠癌、宫颈癌、乳腺癌等组织中CEA均呈高水平表达，且随着病情进展，CEA表达水平亦逐步升高。有报道称 [<xref ref-type="bibr" rid="hanspub.37072-ref10">10</xref>] 动态监测机体CEA表达水平可监测肿瘤患者病情进展与预后。然而CEA的特异性较低，且不同肿瘤分期的敏感性亦有一定差异，如鳞癌敏感性为48.1%，腺癌为59.3%。研究指出 [<xref ref-type="bibr" rid="hanspub.37072-ref11">11</xref>] 当血清CEA表达超低临界值能够判断发生肿瘤的风险较高，但即使血清CEA表达低于临界值，亦不能排除恶性肿瘤的可能，为此临床上常需要联合其他肿瘤标志物鉴别，以确定病变类型。CA242是一种新型肿瘤标志物，属于唾液酸化的糖蛋白，当消化道发生恶性肿瘤时，机体表达升高，对结直肠癌、胰腺癌具有较高特异性和敏感性。桂林报道称 [<xref ref-type="bibr" rid="hanspub.37072-ref12">12</xref>] 因胃癌死亡的患者中，超过一半患者血清CA242表达水平于3个月内明显上升，且与肿瘤进展、肿瘤体积及残留肿瘤细胞有关。研究亦证实 [<xref ref-type="bibr" rid="hanspub.37072-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.37072-ref14">14</xref>] 血清CA242表达异常升高的胃癌患者生存质量较差，是患者预后的风险因子。CA199是一种低聚糖类肿瘤标志物，与胃癌、结肠癌、胰腺癌、胆管癌相关，亦称胃肠癌相关抗原。在正常机体组织含量极低，在消化道恶性肿瘤患者中血清CA199表达显著升高，且与肿瘤分期有关。王国凤 [<xref ref-type="bibr" rid="hanspub.37072-ref15">15</xref>] 对胃癌患者、慢性浅表性胃炎患者、健康人群血清CA199进行检测，结果显示胃癌患者血清CA199水平明显高于慢性浅表性胃炎和健康人群，提示CA199参与了胃癌病情进展，可作为胃癌早期诊断的潜在指标。</p><p>本研究对胃癌患者、胃部不适患者血清CA724、CEA、CA242、CA199进行检测，结果发现胃癌患者血清CA724、CEA、CA242、CA199均显明显高于对照组，证实了CA724、CEA、CA242、CA199均是胃癌的血清诊断指标。陈舒颖报道称 [<xref ref-type="bibr" rid="hanspub.37072-ref16">16</xref>] 胃癌患者临床资料进行回顾性分析，结果显示胃癌患者血清CA724、CEA、CA242、CA199显著升高，且高肿瘤分期患者CA724、CEA、CA242、CA199明显升高。本研究结果亦显示III~IV期胃癌患者血清CA724、CEA、CA242、CA199水平明显高于I~II期，进一步证实了CA724、CEA、CA242、CA199作为胃癌的病情严重程度评估的可能，与章跃报道结论相一致 [<xref ref-type="bibr" rid="hanspub.37072-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.37072-ref18">18</xref>]。为了更好的评价对胃癌的诊断价值，本研究对血清CA724、CEA、CA242、CA199指标ROC曲线进行分析，结果显示联合检验为AUC为0.940，联合检验能够提高敏感性、特异性和准确度，提示CA724、CEA、CA242、CA199指标联合检验对胃癌的诊断价值最高，能够避免单项检测所造成的漏诊及误诊，特别适用于临床病理资料缺乏的早期诊断。周萍研究也证实 [<xref ref-type="bibr" rid="hanspub.37072-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.37072-ref20">20</xref>] 联合检测常用的肿瘤标志物，能够提高单项指标检测的特异性和准确性，有利于早期筛查胃癌。</p></sec><sec id="s7"><title>5. 结论</title><p>综上所述，胃癌患者血清CA724、CEA、CA242、CA199均显著升高，通过联合检验四种指标诊断价值更高，可以作为胃癌诊断、鉴别的有效指标。然而本研究样本量偏少，所得出的结果可能存在偏倚，尚需进一步研究证实。</p></sec><sec id="s8"><title>文章引用</title><p>宋 诗,王丽丽,潘 妮,齐卫卫,邱文生. 血清CA724、CEA、CA242、CA199联合检验对胃癌的诊断价值分析Analysis of the Diagnostic Value of Serum CA724, CEA, CA242, CA199 for Gastric Cancer[J]. 临床医学进展, 2020, 10(08): 1655-1662. https://doi.org/10.12677/ACM.2020.108248</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37072-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">左婷婷, 郑荣寿, 曾红梅, 等. 中国胃癌流行病学现状[J]. 中国肿瘤临床, 2017, 44(1): 52-58.</mixed-citation></ref><ref id="hanspub.37072-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, N., Deng, J.Y., Ding, X.-W., et al. (2015) Tumor Volume as a Prognostic Factor Was Superior to the Seventh Edition of the PT Classification in Resectable Gastric Cancer. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 41, 315-322.  
&lt;br&gt;https://doi.org/10.1016/j.ejso.2014.11.045</mixed-citation></ref><ref id="hanspub.37072-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Li, R., Feng, F., Chen, Z.-Z., et al. (2015) Sensitive Detection of Carcinoembryonic Antigen Using Surface Plasmon Resonance Biosensor with Gold Nanoparticles Signal Amplification. Talanta: The International Journal of Pure and Applied Analytical Chemistry, 140, 143-149. &lt;br&gt;https://doi.org/10.1016/j.talanta.2015.03.041</mixed-citation></ref><ref id="hanspub.37072-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">刘光艺, 黄镇, 王子卫, 等. 第8版国际抗癌联盟和美国癌症联合委员会胃癌TNM分期系统简介及解读[J]. 腹部外科, 2017, 30(4): 241-245.</mixed-citation></ref><ref id="hanspub.37072-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Luo, G.Q., Zhou, Y.H., Yi, W., et al. (2015) Lactotransferrin Expression Is Downregulated and Affects the Mitogen-Activated Protein Kinase Pathway in Gastric Cancer. Oncology Letters, 9, 2409-2413.  
&lt;br&gt;https://doi.org/10.3892/ol.2015.3011</mixed-citation></ref><ref id="hanspub.37072-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">朱攀. 肿瘤标志物CEA、CA242及CA724检测对老年肺癌病情及预后评估的临床价值分析[J]. 实用老年医学, 2018, 32(8): 752-754.</mixed-citation></ref><ref id="hanspub.37072-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">谢海涛. 肿瘤标志物CA724、CA199、CA242、CEA联合检测在老年胃癌诊断中的应用[J]. 中国老年学杂志, 2017, 37(1): 127-129.</mixed-citation></ref><ref id="hanspub.37072-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">闫宏博, 季福建, 吴元玉, 等. CEA、CA724、CA19-9对残胃癌诊断的意义及其相关性分析[J]. 中国实验诊断学, 2019, 23(2): 207-210.</mixed-citation></ref><ref id="hanspub.37072-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">林凯, 宋莎莎, 章礼久, 等. 胃蛋白酶原、癌胚抗原、黏蛋白类癌胚抗原联合检测对胃癌的诊断及鉴别诊断效能[J]. 山东医药, 2017, 57(47): 95-97.</mixed-citation></ref><ref id="hanspub.37072-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Honma, M., Iinuma, S., Kanno, K., et al. (2015) Correlation of Disease Activity and Serum Level of Carcinoembryonic Antigen in Acquired Idiopathic Generalized Anhidrosis: A Case Report. The Journal of Dermatology, 42, 900-902.  
&lt;br&gt;https://doi.org/10.1111/1346-8138.12926</mixed-citation></ref><ref id="hanspub.37072-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kim, J.R., Jang, J.-Y., Kang, M.J., et al. (2015) Clinical Implication of Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 for the Prediction of Malignancy in Intraductal Papillary Mucinous Neoplasm of Pancreas. Journal of Hepato-Biliary-Pancreatic Sciences, 22, 699-707. &lt;br&gt;https://doi.org/10.1002/jhbp.275</mixed-citation></ref><ref id="hanspub.37072-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">桂林, 黄远帅. 血清CA72-4, CA242, CA19-9和CEA的PCA-决策树模型对胃癌的诊断价值[J]. 现代检验医学杂志, 2017, 32(1): 57-60.</mixed-citation></ref><ref id="hanspub.37072-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">张续民, 冯丽, 吕鹏彪, 等. CEA及CA242检测对胃癌根治性手术患者预后判断效果[J]. 贵州医药, 2019, 43(10): 1548-1549.</mixed-citation></ref><ref id="hanspub.37072-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">韩梅, 连俊, 马明杰, 等. 血清胃蛋白酶原与肿瘤标志物CEA、CA199、CA242、CA724联合检测对胃癌诊断的价值分析[J]. 河北医药, 2019, 41(23): 3574-3577.</mixed-citation></ref><ref id="hanspub.37072-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">王国凤, 徐宁, 杨涛, 等. 2型糖尿病患者血清胃肠道肿瘤相关抗原CA199的变化及其临床意义[J]. 中国糖尿病杂志, 2017, 25(7): 618-620.</mixed-citation></ref><ref id="hanspub.37072-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">陈舒颖, 邱芳华, 李秋明, 等. 血清DCD、CA199、CA724和CEA联合检测对大肠癌的诊断价值[J]. 实用医学杂志, 2017, 33(15): 2482-2485.</mixed-citation></ref><ref id="hanspub.37072-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">章跃, 罗雨, 徐新亚, 等. 香菇多糖注射液不同疗程给药对奥沙利铂联合卡培他宾治疗胃癌效果及对患者外周血CEA、CA199水平的影响[J]. 中国生化药物杂志, 2017, 37(3): 78-80.</mixed-citation></ref><ref id="hanspub.37072-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">钟平, 陈文芳. 胃液中α1-抗胰蛋白酶、CEA、Ca199、Ca724检测对胃癌诊断价值分析[J]. 现代消化及介入诊疗, 2019, 24(11): 1341-1343.</mixed-citation></ref><ref id="hanspub.37072-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">周萍, 王聪, 赵车冬, 等. CEA、CA199、CA125、CA724联合检测对胃癌的临床诊断价值[J]. 实用癌症杂志, 2017, 32(9): 1427-1429.</mixed-citation></ref><ref id="hanspub.37072-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">吴永伟, 赵刚. CEA、CA724、CA199与PGI、PGII、PGR联合检测在胃癌早期诊断中的价值分析[J]. 川北医学院学报, 2018, 33(6): 836-839.</mixed-citation></ref></ref-list></back></article>